INCYTE REPORTS POSITIVE RESULTS OF JAK INHIBITOR TESTED IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA PATIENTS

  • MPNRF | May 3, 2021

    December 2010

    Incyte Corp. is currently working on phase II clinical trials for their JAK Inhibitor INCB18424. These trials are testing safety and efficacy of this drug, meant to relieve constitutional symptoms in ET and PV patients. Results were reported at the American Society of Hematology’s annual meeting.

    Click here for more information